Y402 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ŭ·Î¶÷Æä´ÏÄÝÁ· | Chloramphenicol group causing adverse effects in therapeutic use |
|
Y403 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸¶Å©·Î¸®µå | Macrolides causing adverse effects in therapeutic use |
|
Y404 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å×Æ®¶ó»çÀÌŬ¸° | Tetracyclines causing adverse effects in therapeutic use |
|
Y405 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å | Aminoglycosides causing adverse effects in therapeutic use |
|
Y405 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ½ºÆ®·¾Å丶À̽Š| Streptomycin causing adverse effects in therapeutic use |
|
Y406 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸®Æĸ¶À̽Š| Rifamycins causing adverse effects in therapeutic use |
|
Y407 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Àü½ÅÇ×Áø±ÕÇ×»ýÁ¦ | Antifungal antibiotics, systemically used causing adverse effects in therapeutic use |
|
Y408 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Àü½ÅÇ×»ýÁ¦ | Other systemic antibiotics causing adverse effects in therapeutic use |
|
Y409 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Àü½ÅÇ×»ýÁ¦ | Systemic antibiotic, unspecified causing adverse effects in therapeutic use |
|
Y41 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ | Other systemic anti-infectives and antiparasitics causing adverse effects in therapeutic use |
|
Y410 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼³Æù¾Æ¹Ìµå | Sulfonamides causing adverse effects in therapeutic use |
|
Y411 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×¹ÌÄÚ¹ÚÅ׸®¾ÆÁ¦ | Antimycobacterial drugs causing adverse effects in therapeutic use |
|
Y412 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׸»¶ó¸®¾ÆÁ¦ ¹× ±âŸ Ç÷¾×³» ¿øÃæ·ù¿¡ ÀÛ¿ëÇÏ´Â ¾à¹° | Antimalarials and drugs acting on other blood protozoa causing adverse effects in therapeutic use |
|
Y413 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç׿øÃæÁ¦ | Other antiprotozoal drugs causing adverse effects in therapeutic use |
|
Y414 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÃæÁ¦ | Anthelminthics causing adverse effects in therapeutic use |
|
Y415 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×¹ÙÀÌ·¯½ºÁ¦ | Antiviral drugs causing adverse effects in therapeutic use |
|
Y418 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¸í½ÃµÈ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ | Other specified systemic anti-infectives and antiparasitics causing adverse effects in therapeutic use |
|
Y418 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÇÏÀ̵å·Ï½ÃÄû³ë¸° À¯µµÃ¼ | Hydroxyquinoline derivatives causing adverse effects in therapeutic use |
|
Y419 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ | Systemic anti-infective and antiparasitic, unspecified causing adverse effects in therapeutic use |
|
Y42 | Ä¡·á½Ã ºÎÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È£¸£¸ó ¹× ±×µéÀÇ ÇÕ¼º ´ë¿ëÇ° ¹× ´ëÇ×Á¦(±æÇ×Á¦) | Hormones and their synthetic substitutes and antagonists,NEC causing adverse effects in therapeutic use |
|